Retirees can draw a crucial investment lesson from studying the two major anniversaries the market is celebrating this month.
I put celebrating in quotes because the first of those two anniversaries was the top of the Internet bubble in March 2000, 18 years ago. The bursting of that bubble is something many of us would just as soon forget, of course, since the Nasdaq Composite index
subsequently lost nearly 80% of its value.
Top 5 Value Stocks To Buy For 2018: Vuzix Corporation(VUZI)
- [By William Patalon III]
Vuzix Corp. (Nasdaq: VUZI) – the “augmented reality” company whose shares more than doubled following our September 2015 recommendation – said that its new “smart glasses” were just honored with a “Wearable Device of the Year” award.
- [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
- [By James E. Brumley]
While the economy’s natural — and recurring — cycles favor different kinds of stocks at different times, not every great trend is necessarily a cyclical one. Sometimes, a trend is rooted in a technological development that changes cultural norms. The advent of the smartphone, for example, has made constant connectivity to the world around part of how we live our daily lives.
These mega-trends present tremendous opportunities for investors too, provided they’re savvy enough to see them coming and play them the right way.
One such mega-trend newly underway right now is the proliferation of wearables… devices that meld clothing (often a wrist-worn device) and technology to perform a function that couldn’t be performed otherwise. Much of the same technology that made the smartphone possible are now ushering in wearables.
It’s not been a smooth beginning. however.
While the buzz was strong and expectations reached a peak two years ago when Fitbit Inc (NYSE:FIT) was all the rage and in the wake of its IPO, the company’s growth wasn’t to be sustained. The company is struggling to muster any growth now, and FIT shares have fallen to a tenth of their value seen in late-2015, when the euphoria was strongest.
Fitbit’s slowdown has been mirrored by other companies in the space. The wearables market only grew 3.1% in Q3 of 2016.
On the flipside, while the debacle of Fitbit — the wearable industry’s iconic company — has been a painful, it’s also been a learning experience. And, it’s not as if the slowdown is unfurling without the wearables market never reaching a respectable size. International Data Corporation estimates were 23 million ‘wearables’ delivered in the third quarter of last year alone.
Moreover, the fizzling of the market hasn’t turned into a reason to swear off wearables as an investment opportunity… quite the opposite, actually. It’s just now become considerably clearer what consumers want an
Top 5 Value Stocks To Buy For 2018: Tronox Limited(TROX)
- [By Lisa Levin]
Shares of Tronox Ltd (NYSE: TROX) were down 23 percent to $19.55. The FTC has challenged Tronox acquisition of Cristal’s titanium dioxide business. Tronox disclosed that it will fight FTC lawsuit seeking to block proposed acquisition of Saudi-owned Cristal.
- [By Lisa Levin]
Tronox Ltd (NYSE: TROX) shares shot up 34 percent to $19.30. Tronox announced plans to acquire Cristal's TiO(2) business and also agreed to sell Alkali Business. Tronox posted a Q4 loss of $0.14 per share on revenue of $548 million.
Top 5 Value Stocks To Buy For 2018: Sunoco LP(SUN)
- [By Lisa Levin]
Friday afternoon, the non-cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Ballard Power Systems Inc. (USA) (NASDAQ: BLDP) and Sunoco LP (NYSE: SUN).
- [By Douglas A. McIntyre]
Exxon Mobil Corp. (NYSE: XOM) is the second largest company in America and the world’s largest oil company. Chevron Corp. (NYSE: CVX) is the third largest company in the United States. Valero Corp. (NYSE: VLO) is among the world’s largest refiners. Sunoco L.P. (NYSE: SUN) is one of North America’s largest owners of stations and convenience stores. BP PLC (NYSE: BP) is among the world’s oil behemoths. Shell is the U.S. branch of oil giant Royal Dutch Shell PLC (NYSE: RDS-A).
- [By ]
That’s the case for Sunoco (NYSE: SUN). After posting a net loss of $0.09 per share in 2017, the gas station owner is expected to swing to a hefty profit of $2.35 per share in 2018. But of the 14 analysts who follow the company, earnings estimates range as low as $1.22 and as high as $3.35 — so there is a high degree of uncertainty.
Top 5 Value Stocks To Buy For 2018: Genfit SA (GNFTF)
- [By SEEKINGALPHA.COM]
In a recent article, we discussed what makes Genfits (OTCPK:GNFTF) Elafibranor one of the most promising candidates in the NASH treatment development space. Given the unmet need (no approved therapies), Elafibranors mechanism of action and the potential it has shown in clinical stages, we see a strong chance of approval if the pivotal Phase 3 study succeeds. In this article, we will briefly discuss the chances of Elafibranors success in clinical stages and Genfits valuation based on the potential of its lead product candidate. We will briefly also discuss the risks to the investment thesis.
Top 5 Value Stocks To Buy For 2018: Theravance Biopharma, Inc.(TBPH)
- [By WWW.KIPLINGER.COM]
The exact date Theravance Biopharma Inc. (TBPH) intends to release a phase 3 update on COPD treatment Revefenacin isnt known. The company simply said in a prior communication with the market it would be sharing an interim look at the trials progress sometime in early Q4.